Johnson & Johnson opened higher at $280.00, compared with its previous close of $275.20. In the last trading session, the stock traded between $275.39 and $282.02. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Johnson & Johnson is now worth
$ 169.14
giving a profit of
$ 69.14 (69.14%)
Note: Past profits do not guarantee future returns.
Rating from 17 Analysts
Today's Change
+$0.29 (+0.11%)
Day High
$282.02
Day Low
$275.39
Day Open
$280.00
Prev Close
$275.20
Volume
25,26,073
1W Return
2.93%
1M Return
2.94%
3M Return
3.71%
6M Return
21.17%
1Y Return
47.64%
Market Cap ($ Mn)
6,63,187
PE Ratio
31.06
PB Ratio
7.60
PEG Ratio
5.80
ROE
34.46%
ROCE
23.45%
EPS (TTM)
$0.09
1 Week
2.93%
1 Month
2.94%
3 Months
3.71%
6 Months
21.17%
9 Months
21.21%
Johnson & Johnson launches Shockwave C2 Aero Fly, halving IVL treatment time
Treatment time reduced to 115 seconds from 230 seconds. Pulse frequency doubled to 2 Hz for faster calcium modification. Pause time between cycles cut by 50% to five seconds. Device targets rising cath lab volumes driven by CAD prevalence.
10 days agoJ&J TREMFYA sustains fistula remission in 48-week Crohn's study
TREMFYA maintained combined fistula remission through Week 48 in Phase 3 FUZION study. Remission rate in 100 mg dose group rose from 28% at Week 24 to 35% at Week 48. Results support TREMFYA use in difficult-to-treat Crohn's disease manifestations. Findings presented at 2026 United European Gastroenterology Week.
11 days agoLeerink Partners maintains Outperform on Johnson & Johnson, cuts target
Leerink Partners maintains an Outperform rating on Johnson & Johnson. Price target lowered from $276 to $272 by analyst David Risinger. The reduction marks a $4 decrease in the projected share value.
15 days agoJohnson & Johnson shares fall as MedTech sales miss consensus
Johnson & Johnson shares declined after MedTech segment sales missed Wall Street consensus. China pricing pressures and European budget cuts cited as primary drivers of the shortfall. International MedTech sales reported as essentially flat for the quarter. Levi & Korsinsky LLP initiated an investigation into potential securities claims for affected investors.
15 days agoJohnson & Johnson Q3 Results: Sales up 5.9%, analysts cut targets
Sales rose 5.9% YoY to $25.39 billion, beating consensus estimates. Adjusted EPS of $2.59 surpassed estimates despite a 7.5% YoY decline. Full-year guidance raised to $101-$101.4 billion in sales and $11.05-$11.15 EPS. Analysts cut price targets citing valuation resets and sector tone concerns. Growth driven by legacy drugs like Stelara, with limited contribution from new launches.
15 days agoRBC Capital maintains Outperform on Johnson & Johnson, cuts PT to $280
RBC Capital maintains Outperform rating on Johnson & Johnson. Price target lowered from $290 to $280 by analyst Trung Huynh. Rating status remains unchanged despite valuation adjustment.
16 days ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,373.70 | +6.63% | $12,93,142.11M | 39.43 | |
| $290.79 | +1.68% | $5,13,859.95M | 72.17 | |
| $146.33 | +3.83% | $3,61,021.28M | 117.74 | |
| $161.10 | +3.22% | $3,27,809.50M | 23.23 | |
| $174.40 | +2.88% | $2,70,478.36M | 24.32 | |
| $460.73 | +1.97% | $2,49,085.38M | 26.86 | |
| $165.61 | +4.03% | $2,05,348.95M | - | |
| $29.95 | +1.70% | $1,70,705.24M | 36.79 | |
| $39.14 | +2.22% | $1,32,689.61M | 11.15 | |
| $61.39 | +1.35% | $1,25,402.27M | 14.67 | |
| $48.68 | -0.12% | $1,05,059.03M | 16.01 | |
| $43.13 | +2.11% | $1,04,182.50M | 23.63 |
An investment of $100 made 5 years ago in Johnson & Johnson is now worth
$ 169.14
giving a profit of
$ 69.14 (69.14%)
Note: Past profits do not guarantee future returns.
